<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00022685</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000068842</org_study_id>
    <secondary_id>UCLA-0009041</secondary_id>
    <secondary_id>IM-T-hLL2-07</secondary_id>
    <secondary_id>UCLA-BB-IND-7124</secondary_id>
    <secondary_id>NCI-G01-2004</secondary_id>
    <nct_id>NCT00022685</nct_id>
  </id_info>
  <brief_title>Epratuzumab in Treating Patients With Non-Hodgkin's Lymphoma</brief_title>
  <official_title>A Phase III Clinical Trial of Immunotherapy With Humanized LL2 IgG (Epratuzumab) in Patients With Low-Grade Follicular, B-Cell Non-Hodgkin's Lymphoma Refractory to Rituxan (Rituximab)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jonsson Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Monoclonal antibodies such as epratuzumab can locate tumor cells and either kill&#xD;
      them or deliver tumor-killing substances to them without harming normal cells.&#xD;
&#xD;
      PURPOSE: Phase III trial to determine the effectiveness of epratuzumab in treating patients&#xD;
      who have low-grade non-Hodgkin's lymphoma that has not responded to chemotherapy or&#xD;
      rituximab.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the safety of epratuzumab in patients with rituximab-refractory low-grade&#xD;
           follicular B-cell non-Hodgkin's lymphoma.&#xD;
&#xD;
        -  Confirm the convenient administration of this drug in this patient population.&#xD;
&#xD;
        -  Determine the efficacy of this drug in terms of objective response rate in these&#xD;
           patients.&#xD;
&#xD;
        -  Determine the duration of response and time to progression in patients treated with this&#xD;
           drug.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Patients receive epratuzumab IV over 15-60 minutes on days 1, 8, 15, and 22.&#xD;
&#xD;
      Patients are followed every 8 weeks for 10 months and then every 3 months for up to 4 years.&#xD;
&#xD;
      PROJECTED ACCRUAL: Approximately 30-100 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>September 2001</start_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <condition>Lymphoma</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>epratuzumab</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed low-grade follicular B-cell non-Hodgkin's lymphoma&#xD;
&#xD;
               -  Small cleaved cell OR&#xD;
&#xD;
               -  Mixed cell&#xD;
&#xD;
          -  The following are ineligible:&#xD;
&#xD;
               -  Primary CNS lymphoma&#xD;
&#xD;
               -  HIV lymphoma&#xD;
&#xD;
               -  Richter's lymphoma&#xD;
&#xD;
               -  Bulky disease (any single mass greater than 10 cm)&#xD;
&#xD;
               -  Pleural effusion with positive cytology for lymphoma&#xD;
&#xD;
          -  Failed prior standard chemotherapy for non-Hodgkin's lymphoma&#xD;
&#xD;
          -  Refractory to at least 1 prior treatment with rituximab&#xD;
&#xD;
               -  Disease progression or failure to achieve objective response within 6 months of&#xD;
                  beginning rituximab therapy&#xD;
&#xD;
          -  At least 1 bidimensionally measurable lesion&#xD;
&#xD;
               -  At least 1.5 cm by CT scan NOTE: A new classification scheme for adult&#xD;
                  non-Hodgkin's lymphoma has been adopted by PDQ. The terminology of &quot;indolent&quot; or&#xD;
                  &quot;aggressive&quot; lymphoma will replace the terminology of &quot;low&quot;, &quot;intermediate&quot;, or&#xD;
                  &quot;high&quot; grade lymphoma. However, this protocol uses the former terminology.&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  Karnofsky 60-100%&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  At least 4 months&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Absolute granulocyte count at least 1,500/mm^3&#xD;
&#xD;
          -  Platelet count at least 50,000/mm^3&#xD;
&#xD;
          -  Hemoglobin at least 8 g/dL&#xD;
&#xD;
          -  Transfusion independent&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin no greater than 1.5 times upper limit of normal (ULN)*&#xD;
&#xD;
          -  Alkaline phosphatase less than 2 times ULN*&#xD;
&#xD;
          -  AST less than 2 times ULN* NOTE: *Unless lymphoma-related&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine no greater than 1.5 times ULN unless lymphoma-related&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No other malignancy within the past 5 years except squamous or basal cell skin cancer&#xD;
             or carcinoma in situ of the cervix&#xD;
&#xD;
          -  No other serious condition or infection that would preclude study participation&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for 3 months after study&#xD;
             participation&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 12 weeks since prior autologous stem cell transplantation&#xD;
&#xD;
          -  No prior radioimmunoconjugate therapies&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No more than 4 prior treatment regimens&#xD;
&#xD;
          -  At least 4 weeks since prior chemotherapy&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  At least 2 weeks since prior corticosteroids&#xD;
&#xD;
          -  No concurrent steroids&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  See Biologic therapy&#xD;
&#xD;
          -  At least 4 weeks since prior radiotherapy to target lesion&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  At least 4 weeks since prior major surgery unless recovered&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  At least 4 weeks since prior experimental therapies&#xD;
&#xD;
          -  No other concurrent investigational or therapeutic agents&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter J. Rosen, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Jonsson Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jonsson Comprehensive Cancer Center, UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095-1781</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2003</verification_date>
  <study_first_submitted>August 10, 2001</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>December 18, 2013</last_update_submitted>
  <last_update_submitted_qc>December 18, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 19, 2013</last_update_posted>
  <keyword>recurrent grade 1 follicular lymphoma</keyword>
  <keyword>recurrent grade 2 follicular lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epratuzumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

